Cat. No. 3335
Chemical Name: 5-[1,2-Dihydro-2-oxo-3H-indol-3-yli
Biological ActivityATP-competitive PDGFR, VEGF and FGFR inhibitor (IC50 values are 0.06, 2.43, 3.04 and > 100 μM at PDGFRβ, VEGFR2, FGFR1 and EGFR respectively). Inhibits proliferation of HUVEC and NIH3T3 cells in vitro (IC50 values are 0.41, 9.3 and 16.5 μM for VEGF, FGF and PDGF-stimulated growth respectively) and induces > 75% growth inhibition against a broad range of tumor types in vivo. Exhibits antiangiogenic, anti-inflammatory, antimetastatic and proapoptotic activity and is orally active.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Sun et al (1999) Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J.Med.Chem. 42 5120. PMID: 10602697.
Laird et al (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60 4152. PMID: 10945623.
Yamamoto et al (2008) TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res. 68 9754. PMID: 19047154.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: SU 6668, supplier, FGFR, VEGFR, PDGFR, inhibitors, Fibroblast, Growth, Factor, Receptors, Receptor, Tyrosine, Kinases, RTKs, Platelet, Derived, Vascular, Endothelial, KDR, Flt, SU6668
Find multiple products by catalog number
New Products in this Area
Potent PDGFR and VEGFR inhibitorNVP ADW 742
ATP-competitive inhibitor of IGF1RKRCA 0008
Potent Ack1 and ALK dual inhibitor; orally bioavailableDDR1-IN-1 dihydrochloride
Selective DDR1 inhibitorHNGF6A
Humanin analog; increases insulin sensitivityHNGF6A
Humanin analog; increases insulin sensitivityGSK 1838705
Potent and selective IR and IGF1R inhibitor; antitumorGSK 1838705
Potent and selective IR and IGF1R inhibitor; antitumorSUN 11602
Basic fibroblast growth factor (bFGF) mimetic; neuroprotectiveSUN 11602
Basic fibroblast growth factor (bFGF) mimetic; neuroprotective
November 15 - 19, 2014
Washington D.C., USA